HIV Rapid Entry Program Improves Access to Patient Care


A rapid entry program decreased time to first provider appointment, time to initiation of ART and time to viral suppression.

Jonathan Colasanti, MD, MSPH, Emory University School of Medicine

Jonathan Colasanti, MD, MSPH, Emory University School of Medicine

Jonathan Colasanti, MD, MSPH

At the 25th Conference on Retroviruses and Opportunistic Infections (CROI), researchers concluded that in an economically and socially disenfranchised population in the South, time to viral suppression for HIV patients was significantly improved through implementation of rapid entry programs.

Jonathan Colasanti, MD, MSPH, Emory University School of Medicine, and researchers assessed the effectiveness of rapid entry programs in the Southern US, since data from select populations demonstrate rapid entry program efficacy. Aside from this study, no rapid entry programs have been reported from the Southern US.

“Significant resources and effort were needed to implement this program, suggesting that more data are needed to determine which populations will benefit most from rapid start of ART in the US,” Colasanti said in his presentation.

Data from test and treat or rapid antiretroviral therapy (ART) approaches have improved linkage to care, rates of viral suppression and time to viral suppression in South Africa, Haiti and San Francisco, which may in turn lead to better retention in care.

From May 16, 2016-July 31, 2016, the feasibility and effectiveness of the rapid entry program was evaluated in a large Ryan White funded clinic in Atlanta, Georgia, which serves a predominantly minority and economically disadvantaged population.

Researchers aimed to enroll patients in the clinic, complete a social needs assessment, provider visit, labs and give an opinion to begin ART within 72 hours of presenting to clinic.

In order to assess the effectiveness of the program, the intervention group was compared to new enrollees of the clinic from the months preceding the rapid entry program Jan. 1, 2016-May 15, 2016.

Inclusion criteria included HIV positive patients, new to the clinic — not necessarily new to the diagnosis — viremic at intake and ≥ 16 years old. Researchers followed up with each group of patients at 6 months.

The primary outcome was the time from presentation to clinic for enrollment to viral suppression, while the secondary outcomes included viral suppression <200 c/mL, attending first scheduled provider visit, time to scheduled provider visit, time to first attended provider visit, and time to ART initiation.

A survival analysis was used to compare viral suppression for the groups, while researchers used linear regression models for secondary outcomes.

Sample size included 118 pre-rapid entry program and 91 post-rapid entry program.

Pre-rapid entry program demographics include age 33, 81% male, 86% Black, 60% men who have sex with men, 58% uninsured, an annual income of $8,808, 67% unstably housed, 9% incarcerated in the last 6 months, 42% active substance use, CD4 141 cells/uL and 59% ART naïve. The post-rapid entry program, however, differed in age at 38 years old.

The median time to viral suppression decreased from 63 days to 45 days post-rapid entry program.

This is the largest, rapid entry cohort described in the US Time to viral suppression, in an economically and socially disenfranchised population in the South.

The findings concluded that through implementation of a rapid entry program time to first provider appointment, time to initiation of ART and time to viral suppression all decreased, however, the proportion of patients achieving viral suppression did not decrease.

Viral suppression, significantly improved through implementation of a rapid entry program, was likely due to shortening the time to initial provider visit and ART prescription, the researchers said.

Rapid entry programs are feasible in areas of the country with the greatest number of new infections.

Colasanti, in an interview, thinks these programs are critically important in areas like the South, where stigma is so strong, there’s leftover systemic racism and mistrust in the medical system — the impact of these programs need to be further studied.

“I think it’s up to us to continue to demand from our health systems, from our other state or federal funding sources, that dollars need to be poured into this, really because it’s the right thing to do,” he said.

Click here to sign up for more MD Magazine content and updates.

Related Coverage >>>

Mental Health, a Crucial Component to Ending HIV Epidemic

Raltegravir Pharmacokinetic Variability Not Impacted by All Antacids

Adherence to ASCVD Guidelines Is Critical to Minimize Risk of CVD in HIV Population

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
© 2024 MJH Life Sciences

All rights reserved.